GRI Stock Analysis: Buy, Sell, or Hold?
GRI - GRI Bio, Inc. Common Stock
$1.92
0.08 (4.35%)
▲
5d:
-17.24%
30d:
-5.88%
90d:
-18.99%
WAIT
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When GRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GRI is down 17.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GRI is down 17.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GRI is currently trading at $1.92, which is considered oversold relative to its 30-day fair value range of $2.04 to $2.26.
Technical Outlook: Technically, GRI is showing sideways momentum. The price is currently testing key support at $1.97. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: GRI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.00 (+1041.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GRI is showing sideways momentum. The price is currently testing key support at $1.97. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: GRI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.00 (+1041.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.04 -
$2.26
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.3%)
- BULLISH: Trading 1041.3% below Wall St target ($21.00)
- WARNING: Recommendation downgraded due to -17.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.04 -
$2.26
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.97
Resistance Level
$2.31
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.73
Wall Street Target
$21.00
(+1041.3%)
Share & Embed Analysis
Last updated: June 25, 2026 10:16 AM ET
Data refreshes hourly during market hours. Next update: 11:16 AM
Data refreshes hourly during market hours. Next update: 11:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 60 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 69 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
